153 related articles for article (PubMed ID: 14555308)
1. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
[TBL] [Abstract][Full Text] [Related]
2. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
3. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
4. [Essential thrombocythemia: a myeloproliferative state on the rise. Clinico-biological study and course of 44 cases].
Sánchez Fayos J; Outeiriño J; Prieto E; Pérez Saenz MA; Calabuig T; Román A; Olabarría E; Valero ML
Sangre (Barc); 1992 Feb; 37(1):17-24. PubMed ID: 1585233
[TBL] [Abstract][Full Text] [Related]
5. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
6. The number of circulating CD34 positive cells is the best preleukapheresis parameter for predicting the quality of peripheral blood progenitor cell harvest.
Feugier P; Schooneman F; Humbert JC; Bordigoni P; Witz F; Monnez JM; Janot C
Nouv Rev Fr Hematol (1978); 1995; 37(6):301-5. PubMed ID: 8907623
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of red cell distribution width in polycythemia vera].
Yonemitsu H; Kodama A; Sakuma H; Oyama M; Shimada T; Tabata Y
Rinsho Byori; 1989 Jul; 37(7):813-8. PubMed ID: 2607651
[TBL] [Abstract][Full Text] [Related]
8. Circulating erythroid progenitors in patients with 'spent' polycythaemia vera and myelofibrosis with myeloid metaplasia.
Kornberg A; Fibach E; Treves A; Goldfarb A; Rachmilewitz EA
Br J Haematol; 1982 Dec; 52(4):573-8. PubMed ID: 7138787
[TBL] [Abstract][Full Text] [Related]
9. Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study.
Remacha AF; Montserrat I; Santamaria A; Oliver A; Barceló MJ; Parellada M
Haematologica; 1997; 82(4):406-10. PubMed ID: 9299851
[TBL] [Abstract][Full Text] [Related]
10. [Radioimmunometric determination of histamine in myeloproliferative syndromes].
Bettelheim P; Valent P
Wien Klin Wochenschr; 1989 Oct; 101(20):706-10. PubMed ID: 2480027
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
12. [Polycythemia: primary or secondary? The differential diagnostic value of stem cell cultures].
Küng C; Huxol H; Müller R; Speck B; Nissen C
Schweiz Med Wochenschr; 1993 Jan; 123(3):53-6. PubMed ID: 8426948
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of familial occurrence of thrombocythaemia and/or thrombocytosis.
Randi ML; Fabris F; Visentin I; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(5):695-9. PubMed ID: 2465250
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia.
Le Bousse-Kerdilès MC; Chevillard S; Charpentier A; Romquin N; Clay D; Smadja-Joffe F; Praloran V; Dupriez B; Demory JL; Jasmin C; Martyré MC
Blood; 1996 Dec; 88(12):4534-46. PubMed ID: 8977245
[TBL] [Abstract][Full Text] [Related]
15. Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders.
Douer D; Fabian I; Cline MJ
Br J Haematol; 1983 Jul; 54(3):373-81. PubMed ID: 6574788
[TBL] [Abstract][Full Text] [Related]
16. Increased circulating neutrophils with surface receptor activity for immunoglobulin G in polycythemia vera and myeloid metaplasia.
Gilbert HS; Goldberg R; Ward L
Blood; 1979 Jun; 53(6):1106-13. PubMed ID: 444652
[TBL] [Abstract][Full Text] [Related]
17. Essential thrombocythemia following polycythemia vera: an unusual sequence.
Randi ML; Barbone E; Zerbinati P; Soini B; Rossi C; Girolami A
J Med; 1996; 27(5-6):363-8. PubMed ID: 9151204
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera].
Nagai M; Tasaka T; Kamano H; Ohnishi H; Taoka T; Ikeda K; Kubota Y; Tanaka T; Irino S
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3267-70. PubMed ID: 3196045
[TBL] [Abstract][Full Text] [Related]
19. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
Appelbaum FR
Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
[TBL] [Abstract][Full Text] [Related]
20. Studies on the phagocytic activity of neutrophilic leukocytes.
Brandt L
Scand J Haematol Suppl; 1967; 2():1-126. PubMed ID: 5243720
[No Abstract] [Full Text] [Related]
[Next] [New Search]
